Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain, and online, on March 22-25, 2026. This meeting brought together clinicians, researchers, nurses, and patients to discuss the latest updates in the field of blood and marrow transplantation and cellular therapies.

EBMT 2026

The 52nd Annual Meeting of the EBMT
22–25 March 2026 | Madrid, Spain

EBMT 2026

The 52nd Annual Meeting of the EBMT
22–25 March 2026 | Madrid, Spain
The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain, and online, on March 22-25, 2026. This meeting brought together clinicians, researchers, nurses, and patients to discuss the latest updates in the field of blood and marrow transplantation and cellular therapies.
View all videos

Latest Videos

View all
5:42
Approaching the sequencing of bispecific antibodies and CAR-T in multiple myeloma
Mohamad Mohty • 24 Mar 2026
4:20
Insights into the EBMT Consensus on transplantation in Hodgkin lymphoma
Anna Sureda • 18 Mar 2026
1:44
The impact of donor type on transplant outcomes in myelofibrosis
Juan Carlos Hernández-Boluda • 23 Mar 2026
2:51
Mitigating and managing key infections that patients are at risk of following CAR-T
Eleftheria Kampouri • 24 Mar 2026

Transplantation

View all
2:38
Incidence & management of TA-TMA in settings with limited access to biomarkers and targeted therapy
Nour Ben Abdeljelil • 23 Mar 2026
1:50
MaaT013 pooled allogeneic microbiotherapy in refractory GI acute GvHD: results of the ARES trial
Florent Malard • 24 Mar 2026

CAR-T & Cellular Therapy

View all
4:06
Factors contributing to the reduction in the incidence of higher-grade CRS and ICANS
Marion Subklewe • 24 Mar 2026
4:27
The rapidly evolving field of CAR-T: developing approaches for MF, autoimmune disease & solid tumors
Alex Rampotas • 24 Mar 2026

Multiple Myeloma

View all
2:46
Anti-CD38 induction and consolidation approaches in transplant-eligible newly diagnosed myeloma
Jesús San Miguel • 26 Mar 2026
4:32
The outcomes of patients with t(4;14) multiple myeloma after autologous transplantation
Joanna Drozd-Sokołowska • 2 Apr 2026

Lymphoma

View all
1:43
Is autologous transplantation still relevant in DLBCL in the CAR-T era?
Leyre Bento De Miguel • 27 Mar 2026
3:31
Outcomes after anti-CD19 CAR T-cell therapy in primary mediastinal B-cell lymphoma
Rémy Duléry • 23 Mar 2026

Leukemia

View all
2:15
Managing pediatric patients with B-ALL: treatment strategies & advice for physicians
Antonio Pérez-Martínez • 24 Mar 2026
2:35
Older matched sibling donor vs young haploidentical donor for alloSCT in secondary AML in CR1
Arnon Nagler • 20 Mar 2026

Non-Malignant

View all
2:48
Key considerations when selecting patients with thalassemia or SCD for gene therapy
Rabi Hanna • 25 Mar 2026
1:23
The potential of using abatacept to mitigate transplant-related toxicities in hemoglobinopathies
Alexander Ngwube • 23 Mar 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals